The Switzerland Life Sciences Trend Analysis 2025, powered by Biotechgate, provides a comprehensive overview of the country’s dynamic biotech, pharma, and medtech sectors. The latest report highlights key industry developments, including the distribution of 2,832 life science companies, with a strong presence in biotechnology therapeutics, diagnostics, and R&D services.
The analysis showcases trends in clinical pipeline activity, with insights into biotech assets in development across various phases. It also examines venture financing trends, revealing the top private equity rounds and M&A deals that shaped the Swiss biotech landscape in 2024. Additionally, the report presents a regional breakdown of company distributions, highlighting the leading cantons driving innovation.
Designed as a strategic tool for investors, business developers, and industry professionals, this report enables data-driven decision-making by identifying emerging opportunities, funding patterns, and partnership prospects within the Swiss life sciences ecosystem.